Estrella Immunopharma, Inc. (ESLA)
$
1.01
-0.01 (-0.99%)
Key metrics
Financial statements
Free cash flow per share
-0.4974
Market cap
37.6 Million
Price to sales ratio
0
Debt to equity
0
Current ratio
0.7478
Income quality
2.0425
Average inventory
0
ROE
-1.5632
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Estrella Immunopharma, Inc. is a preclinical-stage biopharmaceutical company focused on developing T-cell therapies for blood cancers and solid tumors in the United States. The company reported an income before tax of -$7,310,098.00 showcasing its pre-tax profitability. With a gross profit standing at $0.00 the company highlights its profitability from core operations. The total costs and expenses for the company are $7,310,098.00 reflecting its overall spending strategies in research and development. Furthermore, the net income ratio is 0.00 indicating the company's profitability margin, while the earnings per share (EPS) is reported at -$0.21 marking the company's profitability on a per-share basis. The lead product candidates developed by Estrella include EB103, aimed at treating diffuse large B-cell lymphoma, which is currently in preclinical trials, and EB104, targeting diffuse large B-cell lymphoma and acute lymphocytic leukemia. The company has also established a collaborative partnership with Imugene Limited to develop solid tumor treatments utilizing Imugene's product candidate CF33-CD19t alongside EB103. Estrella Immunopharma, Inc. is based in Emeryville, California, and aims to make significant contributions to oncology. In terms of market positioning, the stock is affordable at $1.02 making it suitable for budget-conscious investors. However, the stock has a low average trading volume of 53,076.00 indicating lower market activity. With a market capitalization of $36,512,790.00 the company is classified as a small-cap player, demonstrating its emerging presence in the market. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape, and it belongs to the Healthcare sector, driving innovation and growth. Through its strategic initiatives and focused product development, Estrella Immunopharma, Inc. seeks to play a vital role in advancing healthcare solutions.
Is Estrella Immunopharma, Inc. (ESLA) a good investment?
Investing in Estrella Immunopharma, Inc. (ESLA) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bearish outlook. Always conduct your own research before investing.
What is Estrella Immunopharma, Inc. (ESLA)'s stock forecast?
Analysts predict Estrella Immunopharma, Inc. stock to fluctuate between $0.63 (low) and $3.23 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Estrella Immunopharma, Inc.'s market capitalization?
As of 2025-05-30, Estrella Immunopharma, Inc.'s market cap is $36,512,790, based on 36,165,600 outstanding shares.
How does Estrella Immunopharma, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Estrella Immunopharma, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Estrella Immunopharma, Inc. (ESLA) stock?
To buy Estrella Immunopharma, Inc. (ESLA) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ESLA. Place an order (Market, Limit, etc.).
What is the best time to invest in Estrella Immunopharma, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Estrella Immunopharma, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$0.21 | Growth: 23.53%.
Where can I find Estrella Immunopharma, Inc.'s investor relations reports?
Visit https://www.estrellabio.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Estrella Immunopharma, Inc.?
You can explore historical data from here
What is the all-time high and low for Estrella Immunopharma, Inc. stock?
All-time high: $5.62 (2023-10-02) | All-time low: $0.63 (2024-10-31).
What are the key trends affecting Estrella Immunopharma, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
businesswire.com
2 days ago
EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that the first patient has been dosed in the second cohort of its dose escalation study of Phase I/II STARLIGHT-1 trial for EB103, a CD19-redirected ARTEMIS® T-cell therapy to treat patients with Advanced B-Cell Non-Hodgkin's Ly.
businesswire.com
3 months ago
EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that CB Capital Partners has initiated coverage on the Company with a Buy rating and a price target of $14.00. “We appreciate CB Capital's detailed evaluation of our proprietary ARTEMIS® T-cell platform and the progress we have.
businesswire.com
3 months ago
EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) (“Estrella” or the “Company”), a clinical stage biopharmaceutical company developing CD19-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced the successful completion of the first dose cohort in its ongoing STARLIGHT-1 Phase I/II clinical trial. Following a review of safety and efficacy data, the Data and Safety Monitoring Board (DSMB) has approved the initiation of th.
businesswire.com
3 months ago
EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) (“Estrella” or the “Company”), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that D. Boral Capital LLC (“D. Boral Capital”), a leading investment bank, has initiated coverage on the Company, assigning a Buy rating to Estrella and established a 12-month price target of $16.00. Valuation Highlights.
businesswire.com
8 months ago
EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) (“Estrella” or the “Company”), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that the first patient enrolled in its STARLIGHT-1 Phase I/II clinical trial has achieved a complete response (CR) one month after receiving an infusion of EB103 CD19- Redirected ARTEMIS® T Cells. In a clinical trial, a c.
See all news
